« Previous
Next »
Progress in Pediatric Cardiology
Volume 23, Issue 1
, Pages
39-48
, September 2007
Enzyme-deficiency metabolic cardiomyopathies and the role of enzyme replacement therapy
To access this article, please choose from the options below
☆ PSK has received research grant support and honoraria from Genzyme Corporation. PSK is a member of the Pompe Disease Advisory Board for Genzyme Corporation. rhGAA, in the form of Genzyme's product, Myozyme™, has been approved by the US FDA and the European Union as therapy for Pompe disease. Duke University and inventors for the method of treatment and predecessors of the cell lines used to generate the enzyme (rhGAA) used in these clinical trials may benefit financially pursuant to the University's Policy on Inventions, Patents and Technology Transfer.
PII: S1058-9813(07)00006-9
doi: 10.1016/j.ppedcard.2007.05.005
© 2007 Elsevier Ireland Ltd. All rights reserved.
« Previous
Next »
Progress in Pediatric Cardiology
Volume 23, Issue 1
, Pages
39-48
, September 2007
